Securities code: Guizhou Yibai Pharmaceutical Co.Ltd(600594) securities abbreviation: Guizhou Yibai Pharmaceutical Co.Ltd(600594) Announcement No.: 2022002 Guizhou Yibai Pharmaceutical Co.Ltd(600594) about
Participate in the announcement that Guangdong alliance Qingkailing and other Chinese patent medicine will be selected in the centralized volume procurement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Recently, Guizhou Yibai Pharmaceutical Co.Ltd(600594) (hereinafter referred to as “the company”) participated in the bidding for centralized procurement of Chinese patent medicines such as Qingkailing of Guangdong alliance. According to the publicity form for the proposed winning / alternative results of centralized procurement of Chinese patent medicines such as Qingkailing of Guangdong alliance issued by Guangdong provincial drug trading center on April 8, 2022, the company’s product Aidi injection is proposed to be selected for this centralized procurement. The relevant information is hereby announced as follows:
1、 Basic information of products to be selected
The proposed winning price of publicity materials is proposed to be supplied to the province, the specification of procurement indications is proposed to be selected, and the quantity is proposed to be selected
Species name lattice (area) cycle
For original
The first year: the enterprise in the alliance area, Guangdong and Shandong
Primary liver
Pre procurement volume in the first year of the procurement period west, Jiangxi
Cancer, lung
100% (3779449 pieces) and Henan and Guangzhou
Cancer, straight
Gain incremental use of West, Hainan
Eddie injected colon cancer,
10ml 18.27 yuan the second year: re report the volume, and the original Guizhou and Qinghai ejaculated liquid for 2 years
The above shall not be less than the first year’s agreement on sea mining, Ningxia
Ba Ma, Fu
Purchase quantity (specific quantity to be determined by each sheet)
Department malignant
Production and construction soldiers in the League area after distribution
tumour
(confirm) group
Wait.
The proposed successful selection and the number of the above varieties are subject to the final data released by Guangdong pharmaceutical trading center.
2、 The impact of this election on the company
In 2020, the sales revenue of Aidi injection was 7377001 million yuan, accounting for 21.61% of the company’s total operating revenue in 2020, and the sales revenue in the alliance area was 2961668 million yuan, accounting for 40.15% of the company’s sales revenue of Aidi Injection in 2020; The sales revenue of Aidi injection from January to September 2021 was 542397800 yuan, accounting for 20.82% of the total operating revenue of the company from January to September 2021, and the sales revenue in the alliance area was 201173900 yuan, accounting for 37.09% of the sales revenue of Aidi injection from January to September 2021.
If the products to be selected are confirmed to be selected, the medical institutions in the alliance area will give priority to the selected products in the centralized drug procurement, and ensure the completion of the agreed procurement volume. Compared with the original benchmark price, the proposed winning price of Aidi injection will decrease by 13%. If the company signs and implements the purchase and sales agreement later, it will help to further expand the sales scope of the winning products, improve the market share of the winning products, enhance the brand influence of the company, and have a positive impact on the long-term development of the company.
3、 Risk tips
(I) the publicity period for the selection of the above products is from April 8, 2022 to April 12, 2022, and the selection results are still uncertain.
(II) the purchase contract related to the above products has not been signed, and the subsequent matters and the impact on the company are still uncertain.
The company will pay close attention to the progress of the matter and fulfill the obligation of information disclosure in time. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Guizhou Yibai Pharmaceutical Co.Ltd(600594) board of directors April 11, 2022
